Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin ii-induced abdominal aortic aneurysms

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 12, 2014, Pages 2617-2623

  Thatcher, Sean E ^a   Zhang, Xuan ^b   Howatt, Deborah A ^a   Yiannikouris, Frederique ^a   Gurley, Susan B ^c,d   Ennis, Terri ^e   Curci, John A ^e   Daugherty, Alan ^a   Cassis, Lisa A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme 2; Angiotensin II; Aortic aneurysms, abdominal; Hypercholesterolemia

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; CHLORDANE; CHOLESTEROL; DIMINAZENE ACETURATE; ELASTASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; DIMINAZENE; DIPEPTIDYL CARBOXYPEPTIDASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; ADVENTITIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BODY WEIGHT; BONE MARROW CELL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME DEFICIENCY; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTIMA; MACROPHAGE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PLASMA RENIN ACTIVITY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; C57BL MOUSE; COMPLICATION; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETICS; HYPERCHOLESTEROLEMIA; KNOCKOUT MOUSE; LEUKOCYTE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGED; ANGIOTENSIN II; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; DIMINAZENE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, LDL; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER;

EID: 84918493360     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304613     Document Type: Article

References (51)

1. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneurysms. Circulation. 2008;117:1883-1889.
2. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995;15:1145-1151.
3. Acosta S, Ogren M, Bergqvist D, Lindblad B, Dencker M, Zdanowski Z. The Hardman index in patients operated on for ruptured abdominal aortic aneurysm: A systematic review. J Vasc Surg. 2006;44:949-954.
4. Dobrin PB, Baker WH, Gley WC. Elastolytic and collagenolytic studies of arteries. Implications for the mechanical properties of aneurysms. Arch Surg. 1984;119:405-409.
5. Powell JT, Brown LC; UK Small Aneurysm Trial. The natural history of abdominal aortic aneurysms and their risk of rupture. Adv Surg. 2001;35:173-185.
6. Daugherty A, Manning MW, Cassis L.A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612.
7. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis L.A. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation. 2004;110:3849-3857.
8. Saraff K, Babamusta F, Cassis L.A., Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1621-1626.
9. Daugherty A, Manning MW, Cassis L.A. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol. 2001;134:865-870.
10. Cassis L.A., Rateri DL, Lu H, Daugherty A. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol. 2007;27:380-386.
11. Iida Y, Xu B, Schultz GM, Chow V, White JJ, Sulaimon S, Hezi-Yamit A, Peterson SR, Dalman RL. Efficacy and mechanism of angiotensin II receptor blocker treatment in experimental abdominal aortic aneurysms. PLoS One. 2012;7:e49642.
12. Hackam DG, Thiruchelvam D, Redelmeier D.A. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet. 2006;368:659-665.
13. Railton CJ, Wolpin J, Lam-McCulloch J, Belo SE. Renin-angiotensin blockade is associated with increased mortality after vascular surgery. Can J Anaesth. 2010;57:736-744.
14. Samson R. Can pharmacologic agents slow abdominal aortic aneurysm growth? Semin Vasc Surg. 2012;25:25-28.
15. Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg. 2010;52:1-4.
16. Thompson A, Cooper JA, Fabricius M, Humphries SE, Ashton HA, Hafez H. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg. 2010;52:55-61.e2.
17. Silverberg D, Younis A, Savion N, Harari G, Yakubovitch D, Sheick Yousif B, Halak M, Grossman E, Schneiderman J. Long-term renin-angiotensin blocking therapy in hypertensive patients with normal aorta may attenuate the formation of abdominal aortic aneurysms. J Am Soc Hypertens. 2014;8:571-577.
18. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
19. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.
20. Thatcher SE, Zhang X, Howatt D.A., Lu H, Gurley SB, Daugherty A, Cassis L.A. Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor-/-mice. Arterioscler Thromb Vasc Biol. 2011;31:758-765.
21. Rateri DL, Howatt D.A., Moorleghen JJ, Charnigo R, Cassis L.A., Daugherty A. Prolonged infusion of angiotensin II in apoE(-/-) mice promotes macrophage recruitment with continued expansion of abdominal aortic aneurysm. Am J Pathol. 2011;179:1542-1548.
22. Kaneko H, Anzai T, Horiuchi K, Kohno T, Nagai T, Anzai A, Takahashi T, Sasaki A, Shimoda M, Maekawa Y, Shimizu H, Yoshikawa T, Okada Y, Yozu R, Fukuda K. Tumor necrosis factor-? converting enzyme is a key mediator of abdominal aortic aneurysm development. Atherosclerosis. 2011;218:470-478.
23. Tang EH, Shvartz E, Shimizu K, Rocha VZ, Zheng C, Fukuda D, Shi GP, Sukhova G, Libby P. Deletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2011;31:261-269.
24. Tazume H, Miyata K, Tian Z, et al. Macrophage-derived angiopoietinlike protein 2 accelerates development of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2012;32:1400-1409.
25. Findeisen HM, Gizard F, Zhao Y, Cohn D, Heywood EB, Jones KL, Lovett DH, Howatt D.A., Daugherty A, Bruemmer D. Telomerase deficiency in bone marrow-derived cells attenuates angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2011;31:253-260.
26. Owens AP III, Rateri DL, Howatt D.A., Moore KJ, Tobias PS, Curtiss LK, Lu H, Cassis L.A., Daugherty A. MyD88 deficiency attenuates angiotensin II-induced abdominal aortic aneurysm formation independent of signaling through Toll-like receptors 2 and 4. Arterioscler Thromb Vasc Biol. 2011;31:2813-2819.
27. Foureaux G, Nogueira JC, Nogueira BS, Fulgêncio GO, Menezes GB, Fernandes SO, Cardoso VN, Fernandes RS, Oliveira GP, Franca JR, Faraco AA, Raizada MK, Ferreira AJ. Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. Invest Ophthalmol Vis Sci. 2013;54:4296-4306.
28. Kulemina LV, Ostrov D.A. Prediction of off-target effects on angiotensinconverting enzyme 2. J Biomol Screen. 2011;16:878-885.
29. Shenoy V, Gjymishka A, Jarajapu YP, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013;187:648-657.
30. Mecca AP, Regenhardt RW, O'Connor TE, Joseph JP, Raizada MK, Katovich MJ, Sumners C. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol. 2011;96:1084-1096.
31. Jin J, Arif B, Garcia-Fernandez F, Ennis TL, Davis EC, Thompson RW, Curci JA. Novel mechanism of aortic aneurysm development in mice associated with smoking and leukocytes. Arterioscler Thromb Vasc Biol. 2012;32:2901-2909.
32. Clark M.A., Diz DI, Tallant EA. Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension. 2001;37:1141-1146.
33. Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens. 1998;11:137-146.
34. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007;292:H736-H742.
35. Hayashi N, Yamamoto K, Ohishi M, Tatara Y, Takeya Y, Shiota A, Oguro R, Iwamoto Y, Takeda M, Rakugi H. The counterregulating role of ACE2 and ACE2-mediated angiotensin 1-7 signaling against angiotensin II stimulation in vascular cells. Hypertens Res. 2010;33:1182-1185.
36. Iyer SN, Averill DB, Chappell MC, Yamada K, Allred AJ, Ferrario CM. Contribution of angiotensin-(1-7) to blood pressure regulation in saltdepleted hypertensive rats. Hypertension. 2000;36:417-422.
37. Santos R.A., Simoes e Silva AC, Maric C, et al. Angiotensin-(1-7) is an endogenous ligand for the g protein-coupled receptor mas. Proc Natl Acad Sci U S A. 2003;100:8258-8263.
38. Shenoy V, Ferreira AJ, Qi Y, et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2010;182:1065-1072.
39. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2010;30:1606-1613.
40. Sampaio WO, Henrique de Castro C, Santos R.A., Schiffrin EL, Touyz RM. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension. 2007;50:1093-1098.
41. Ferreira AJ, Bader M, Santos R.A. Therapeutic targeting of the angiotensinconverting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin-angiotensin system: a patent review. Expert Opin Ther Pat. 2012;22:567-574.
42. Rateri DL, Moorleghen JJ, Knight V, Balakrishnan A, Howatt D.A., Cassis L.A., Daugherty A. Depletion of endothelial or smooth muscle cell-specific angiotensin II type 1a receptors does not influence aortic aneurysms or atherosclerosis in LDL receptor deficient mice. PLoS One. 2012;7:e51483.
43. Cassis L.A., Gupte M, Thayer S, Zhang X, Charnigo R, Howatt D.A., Rateri DL, Daugherty A. ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol. 2009;296:H1660-H1665.
44. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos R.A., Castellano RK, Lampkins AJ, Gubala V, Ostrov D.A., Raizada MK. Structurebased identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51:1312-1317.
45. Haber PK, Ye M, Wysocki J, Maier C, Haque SK, Batlle D. Angiotensinconverting enzyme 2-independent action of presumed angiotensinconverting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension. 2014;63:774-782.
46. Peregrine AS, Mamman M. Pharmacology of diminazene: a review. Acta Trop. 1993;54:185-203.
47. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487:477-481.
48. Paizis G, Tikellis C, Cooper ME, Schembri JM, Lew R.A., Smith AI, Shaw T, Warner FJ, Zuilli A, Burrell LM, Angus PW. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54:1790-1796.
49. Feltenberger JD, Andrade JM, Paraíso A, Barros LO, Filho AB, Sinisterra RD, Sousa FB, Guimarães AL, de Paula AM, Campagnole-Santos MJ, Qureshi M, dos Santos R.A., Santos S.H. Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension. 2013;62:324-330.
50. Police SB, Thatcher SE, Charnigo R, Daugherty A, Cassis L.A. Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2009;29:1458-1464.
51. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadière C, Rénia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest. 2010;120:422-432.